Literature DB >> 33742324

Every Day Counts: a randomized pilot lifestyle intervention for women with metastatic breast cancer.

Patricia Sheean1, Lauren Matthews2, Alexis Visotcky3, Anjishnu Banerjee3, Andrea Moosreiner4, Kimberly Kelley5, Christopher R Chitambar6, Paula E Papanek7, Melinda Stolley8.   

Abstract

PURPOSE: To explore the feasibility, adherence, safety and potential efficacy of Every Day Counts; a randomized pilot trial designed for women with metastatic breast cancer (MBC) framed by the American Cancer Society nutrition and physical activity (PA) guidelines
METHODS: Women with clinically stable MBC were recruited to complete an interview, dual energy X-ray absorptiometry imaging and phlebotomy at baseline and post-intervention. Multidimensional quality of life, symptom burden, lifestyle behaviors (nutrition and PA) and biomarkers of prognosis were procured and quantified. Women were randomized to the immediate intervention or a waitlist control arm. The 12-week intervention included a curriculum binder, lifestyle coaching (in-person and telephone-based sessions) and intervention support (activity monitor, text messaging, cooking classes.) Women in the waitlist control were provided monthly text messaging.
RESULTS: Forty women were recruited within 9 months (feasibility). Women in the immediate intervention attended 86% of all 12 weekly coaching sessions (adherence) and showed significant improvements in general QOL (p = 0.001), and QOL related to breast cancer (p = 0.001), endocrine symptoms (p = 0.002) and fatigue (p = 0.037), whereas the waitlist control did not (all p values ≥ 0.05) (efficacy). PA significantly increased for women in the intervention compared to control (p < 0.0001), while dietary changes were less evident across groups due to high baseline adherence. No significant changes in biomarkers or lean mass were noted, yet visceral adipose tissue declined (p = 0.001). No intervention-related injuries were reported (safety). Qualitative feedback strongly supports the desire for a longer intervention with additional support.
CONCLUSIONS: Lifestyle interventions are of interest, safe and potentially beneficial for women with MBC. A larger trial is warranted.

Entities:  

Keywords:  Exercise; Lifestyle intervention; Metastatic breast cancer; Nutrition; Quality of life

Mesh:

Year:  2021        PMID: 33742324      PMCID: PMC8206042          DOI: 10.1007/s10549-021-06163-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.624


  65 in total

1.  Exercise and dietary advice intervention for survivors of triple-negative breast cancer: effects on body fat, physical function, quality of life, and adipokine profile.

Authors:  Anne K Swisher; Jame Abraham; Daniel Bonner; Diana Gilleland; Gerald Hobbs; Sobha Kurian; Mary Anne Yanosik; Linda Vona-Davis
Journal:  Support Care Cancer       Date:  2015-03-01       Impact factor: 3.603

2.  Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.

Authors:  Shlomit Strulov Shachar; Allison M Deal; Marc Weinberg; Kirsten A Nyrop; Grant R Williams; Tomohiro F Nishijima; Julia M Benbow; Hyman B Muss
Journal:  Clin Cancer Res       Date:  2016-08-03       Impact factor: 12.531

3.  A cognitive behavioral therapy intervention to promote weight loss improves body composition and blood lipid profiles among overweight breast cancer survivors.

Authors:  Kari Mefferd; Jeanne F Nichols; Bilge Pakiz; Cheryl L Rock
Journal:  Breast Cancer Res Treat       Date:  2006-10-21       Impact factor: 4.872

4.  Development and validation of criterion-referenced clinically relevant fitness standards for maintaining physical independence in later years.

Authors:  Roberta E Rikli; C Jessie Jones
Journal:  Gerontologist       Date:  2012-05-20

5.  Randomized trial of a physical activity intervention in women with metastatic breast cancer.

Authors:  Jennifer A Ligibel; Anita Giobbie-Hurder; Laura Shockro; Nancy Campbell; Ann H Partridge; Sara M Tolaney; Nancy U Lin; Eric P Winer
Journal:  Cancer       Date:  2016-02-12       Impact factor: 6.860

Review 6.  Herceptin (trastuzamab) in advanced breast cancer.

Authors:  J Stebbing; E Copson; S O'Reilly
Journal:  Cancer Treat Rev       Date:  2000-08       Impact factor: 12.111

7.  Fatigue in cancer patients compared with fatigue in the general United States population.

Authors:  David Cella; Jin-Shei Lai; Chih-Hung Chang; Amy Peterman; Mitchell Slavin
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

Review 8.  Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.

Authors:  G N Hortobagyi
Journal:  Semin Oncol       Date:  2001-12       Impact factor: 4.929

9.  Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins.

Authors:  Kathryn H Schmitz; Rehana L Ahmed; Peter J Hannan; Douglas Yee
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-07       Impact factor: 4.254

10.  Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009.

Authors:  Rebecca H Johnson; Franklin L Chien; Archie Bleyer
Journal:  JAMA       Date:  2013-02-27       Impact factor: 56.272

View more
  2 in total

Review 1.  The Effect of Exercise and Nutritional Interventions on Body Composition in Patients with Advanced or Metastatic Cancer: A Systematic Review.

Authors:  Oscar Barnes; Rebekah L Wilson; Paola Gonzalo-Encabo; Dong-Woo Kang; Cami N Christopher; Thomas Bentley; Christina M Dieli-Conwright
Journal:  Nutrients       Date:  2022-05-18       Impact factor: 6.706

2.  Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer.

Authors:  Patricia Sheean; Sandra Gomez-Perez; Cara Joyce; Paula O'Connor; Monica Bojko; Amber Smith; Vasilios Vasilopoulos; Ruta Rao; Joy Sclamberg; Patricia Robinson
Journal:  Breast Cancer Res Treat       Date:  2021-08-13       Impact factor: 4.624

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.